Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Identify the key factors to evaluate retirement index funds in 2024, including fees, diversification, and historical performance context.
21,429 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
A major move in consumer finance tests whether a bank can grow its wallet while keeping customers happy. This article...
Nvidia dominates today’s AI data centers, but the real threat to its throne may be a risk that sits in plain sight. T...
Shopify’s $120 billion revival is unfolding with a burst of revenue and user growth, catching short sellers by surpri...
Grab's CEO recently sold 400,000 Class A shares for about $1.6 million. This insider move raises the question: should...
Whale purchases surge, a technical buy signal reappears, and exchange balances retreat as XRP eyes a potential breako...
As memory chip inventories weigh on the tech sector, the Dow shows remarkable resilience. This article breaks down wh...
Thinking about should tesla stock before July 22 earnings? This guide breaks down potential catalysts, risk factors, ...
Two popular names in tech and space economics spark a debate: should you buy SpaceX stock while selling Micron stock,...
Institutional forecasts can move markets, but they require careful scrutiny. This article breaks down why Standard Ch...
A big earnings event could flip the script for Microsoft stock. This article breaks down why the bold idea of a parab...
A long-awaited conversation with lasting impact on culture also carries financial lessons. This article breaks down h...